SCHEMBL2118908

SCHEMBL2118908

Cc1cccc(N(C(C)c2ccccc2F)S(=O)(=O)c2ccc(F)cc2C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.40
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.35
PSEN1 P49768 3/20 0.35
PSEN2 P49810 3/20 0.35
APH1B Q8WW43 3/20 0.35
NCSTN Q92542 3/20 0.35
APH1A Q96BI3 3/20 0.35
PSENEN Q9NZ42 3/20 0.35
HSD11B1 P28845 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
RAB9A P51151 1/20 0.33
FABP4 P15090 1/20 0.33
FABP5 Q01469 1/20 0.33
GAA P10253 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120045 0.91 RECQL (0.40) TSHRMAPK1RECQLMAPTTP53
SCHEMBL10249846 0.90 HSD11B1 (0.42) TSHRMAPK1RECQLMAPTTP53
SCHEMBL2117856 0.87 RECQL (0.46) RECQLMAPTTP53SMN1; SMN2HSD11B1
SCHEMBL2119849 0.76 HSD11B1 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2120059 0.73 PSEN1 (0.44) TSHRMAPK1MAPTSMN1; SMN2PSEN1
SCHEMBL2117809 0.70 SMN1; SMN2 (0.40) TSHRMAPK1MAPTSMN1; SMN2PSEN1
SCHEMBL2119723 0.70 CA1 (0.40) TSHRMAPK1MAPTSMN1; SMN2PSEN1
SCHEMBL2119805 0.68 SMN1; SMN2 (0.42) TSHRMAPK1MAPTSMN1; SMN2PSEN1
SCHEMBL2117553 0.66 HSD11B1 (0.44) TSHRMAPK1MAPTTP53SMN1; SMN2
SCHEMBL2120075 0.65 PSEN1 (0.44) MAPK1MAPTSMN1; SMN2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 TSHR 1240/4885MAPK1 843/4885RECQL 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.